Sorafenib improves alkylating therapy by blocking induced inflammation, invasion and angiogenesis in breast cancer cells

Molecular targeted compounds are emerging as a strategy to improve classical chemotherapy. Herein, we describe that using low dose of the multikinase inhibitor sorafenib improves cyclophosphamide antitumor activity by inhibiting angiogenesis, metastasis and promoting tumor healing in MDA-MB231 xenog...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Lett
Autors principals: Zanotto-Filho, Alfeu, Rajamanickam, Subapriya, Loranc, Eva, Masamsetti, Pragathi, Gorthi, Aparna, Romero, July Carolina, Tonapi, Sonal, Gonçalves, Rosangela Mayer, Reddick, Robert L., Benavides, Raymond, Kuhn, John, Chen, Yidong, Bishop, Alexander J. R.
Format: Artigo
Idioma:Inglês
Publicat: 2018
Matèries:
Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5930000/
https://ncbi.nlm.nih.gov/pubmed/29608984
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.canlet.2018.03.037
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars